Literature DB >> 15548360

Cytokines and chemokines are expressed at different levels in small and large murine colon-26 tumors following intratumoral injections of CpG ODN.

Sanjay Sharma1, Constantine P Karakousis, Hiroshi Takita, Kyu Shin, Stephen P Brooks.   

Abstract

Direct tumor injections of (CpG ODN) into murine colon tumor 26 (CT-26) tumors can induce a potent antitumor response. Tumor size at the beginning of treatment determines the final therapeutic outcome, with smaller tumors responding favorably to CpG ODN therapy whereas large tumors do not. CpG ODN injections in small tumors resulted in tumor necrosis and extensive inflammatory cell infiltration, with average survival that is significantly higher (48.1 +/- 34 days) when compared to control ODN-treated mice (16.1 +/- 3.5 days). Cytokines and chemokines are expressed at different levels in small and large CT-26 tumors following intratumoral injections of CpG ODN. We observed that granulocyte-macrophage colony-stimulating factor and interleukin (IL) 6 are the major cytokines that were overexpressed in CpG ODN-treated small tumors but not in large tumors. Similarly, several chemokines (CXCL1, CCL2, and CCL3) were also significantly higher in CpG ODN-treated small tumors compared to control ODN-treated tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15548360      PMCID: PMC1531655          DOI: 10.1593/neo.04166

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  27 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

Review 2.  CpG motifs in bacterial DNA and their immune effects.

Authors:  Arthur M Krieg
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

3.  Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells.

Authors:  Chandrashekhar Pasare; Ruslan Medzhitov
Journal:  Science       Date:  2003-01-16       Impact factor: 47.728

Review 4.  Intratumoral injection of GM-CSF in perspective - a review.

Authors:  Stephen Brooks; Hiroshi Takita; Kyu Shin; Yisheng Fang; Mary Vaughan; Sanjay Sharma; Constantine P Karakousis
Journal:  J Med       Date:  2003

5.  Intra-tumoral injection of CpG results in the inhibition of tumor growth in murine Colon-26 and B-16 tumors.

Authors:  Sanjay Sharma; Constantine P Karakousis; Hiroshi Takita; Kyu Shin; Stephen P Brooks
Journal:  Biotechnol Lett       Date:  2003-01       Impact factor: 2.461

6.  Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice.

Authors:  Q Zhao; J Temsamani; R Z Zhou; S Agrawal
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1997-10

7.  Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.

Authors:  Klaus Heckelsmiller; Sebastian Beck; Katharina Rall; Bence Sipos; Angelika Schlamp; Evelyn Tuma; Simon Rothenfusser; Stefan Endres; Gunther Hartmann
Journal:  Eur J Immunol       Date:  2002-11       Impact factor: 5.532

8.  TLR9 signals after translocating from the ER to CpG DNA in the lysosome.

Authors:  Eicke Latz; Annett Schoenemeyer; Alberto Visintin; Katherine A Fitzgerald; Brian G Monks; Cathrine F Knetter; Egil Lien; Nadra J Nilsen; Terje Espevik; Douglas T Golenbock
Journal:  Nat Immunol       Date:  2004-01-11       Impact factor: 25.606

9.  Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity.

Authors:  Anke S Lonsdorf; Haydar Kuekrek; Britta V Stern; Bernhard O Boehm; Paul V Lehmann; Magdalena Tary-Lehmann
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

10.  Chemokines in cancer.

Authors:  M J Frederick; G L Clayman
Journal:  Expert Rev Mol Med       Date:  2001-07-18       Impact factor: 5.600

View more
  4 in total

Review 1.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

2.  Gene expression down-regulation in CD90+ prostate tumor-associated stromal cells involves potential organ-specific genes.

Authors:  Laura E Pascal; Young Ah Goo; Ricardo Zn Vêncio; Laura S Page; Amber A Chambers; Emily S Liebeskind; Thomas K Takayama; Lawrence D True; Alvin Y Liu
Journal:  BMC Cancer       Date:  2009-09-08       Impact factor: 4.430

3.  Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists.

Authors:  P L Triozzi; W Aldrich; S Ponnazhagan
Journal:  Cancer Gene Ther       Date:  2011-08-26       Impact factor: 5.987

4.  Tumor-derived granzyme B-expressing neutrophils acquire antitumor potential after lipid A treatment.

Authors:  Amandine Martin; Cédric Seignez; Cindy Racoeur; Nicolas Isambert; Nesrine Mabrouk; Alessandra Scagliarini; Sylvie Reveneau; Laurent Arnould; Ali Bettaieb; Jean-François Jeannin; Catherine Paul
Journal:  Oncotarget       Date:  2018-06-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.